RhumbLine Advisers’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $441K | Buy |
113,981
+7,462
| +7% | +$28.9K | ﹤0.01% | 2763 |
|
|
2025
Q1 | $533K | Buy |
106,519
+1,643
| +2% | +$8.22K | ﹤0.01% | 2539 |
|
|
2024
Q4 | $756K | Sell |
104,876
-4,343
| -4% | -$31.3K | ﹤0.01% | 2399 |
|
|
2024
Q3 | $671K | Buy |
109,219
+1,773
| +2% | +$10.9K | ﹤0.01% | 2512 |
|
|
2024
Q2 | $715K | Buy |
107,446
+22,034
| +26% | +$147K | ﹤0.01% | 2431 |
|
|
2024
Q1 | $869K | Buy |
85,412
+3,998
| +5% | +$40.7K | ﹤0.01% | 2326 |
|
|
2023
Q4 | $916K | Buy |
81,414
+4,051
| +5% | +$45.6K | ﹤0.01% | 2309 |
|
|
2023
Q3 | $201K | Buy |
77,363
+2,291
| +3% | +$5.96K | ﹤0.01% | 3158 |
|
|
2023
Q2 | $265K | Buy |
+75,072
| New | +$265K | ﹤0.01% | 3084 |
|
|
2022
Q2 | – | Sell |
-50,234
| Closed | -$306K | – | 3095 |
|
|
2022
Q1 | $306K | Buy |
50,234
+2,094
| +4% | +$12.8K | ﹤0.01% | 2640 |
|
|
2021
Q4 | $441K | Buy |
48,140
+1,958
| +4% | +$17.9K | ﹤0.01% | 2564 |
|
|
2021
Q3 | $522K | Buy |
46,182
+4,021
| +10% | +$45.5K | ﹤0.01% | 2522 |
|
|
2021
Q2 | $415K | Buy |
+42,161
| New | +$415K | ﹤0.01% | 2648 |
|
|
2017
Q2 | – | Sell |
-177
| Closed | -$43K | – | 2923 |
|
|
2017
Q1 | $43K | Buy |
177
+5
| +3% | +$1.22K | ﹤0.01% | 2826 |
|
|
2016
Q4 | $167K | Buy |
172
+15
| +10% | +$14.6K | ﹤0.01% | 2714 |
|
|
2016
Q3 | $137K | Buy |
157
+31
| +25% | +$27.1K | ﹤0.01% | 2762 |
|
|
2016
Q2 | $92K | Buy |
+126
| New | +$92K | ﹤0.01% | 2924 |
|